Aberrant trophoblastic differentiation in human cancer: An emerging novel therapeutic target (Review).
Oncol Rep
; 51(3)2024 03.
Article
em En
| MEDLINE
| ID: mdl-38240107
ABSTRACT
Various types of human cancer may develop aberrant trophoblastic differentiation, including histological changes and altered expression of ßhuman chorionic gonadotropin (ßhCG). Aberrant trophoblastic differentiation in epithelial cancer is usually associated with poor differentiation, tumor metastasis, unfavorable prognosis and treatment resistance. Since ßhCGtargeting vaccines have failed in an early phase II trial, it is crucial to obtain a better understanding of the molecular pathogenesis of trophoblastic differentiation in human cancer. The present review summarizes the clinical and translational research on this topic with the aim of accelerating the development of an effective targeted therapy. Ectopic expression of ßhCG promotes proliferation, migration, invasion, vasculogenesis and epithelialmesenchymal transition (EMT) in vitro, and enhances metastatic and tumorigenic capabilities in vivo. Signaling cascades modulated by ßhCG include the TGFß receptor pathway, EMTrelated pathways, the cMET receptor tyrosine kinase and mitogenactivated protein kinase/ERK pathways, and the SMAD2/4 pathway. Taken together, these findings indicated that TGFß receptors, cMET and ERK1/2 are potential therapeutic targets. Nevertheless, further investigation on the molecular basis of aberrant trophoblastic differentiation is mandatory to improve the design of precision therapy for this aggressive type of human cancer.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Gonadotropina Coriônica Humana Subunidade beta
/
Neoplasias
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Oncol Rep
/
Oncol. rep
/
Oncology reports
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2024
Tipo de documento:
Article